Compare ADMA Biologics Inc (ADMA) vs Starbucks Corp (SBUX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Starbucks Corp — how do they compare? ADMA Biologics Inc trades at $9.22 (market cap $2.13B), while Starbucks Corp trades at $103.22 (market cap $118.08B). The key difference: Starbucks Corp is far larger — about 55.4× ADMA Biologics Inc's market cap, and Starbucks Corp pays a 2.39% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | SBUX | |
|---|---|---|
Market Cap | $2.13B | $118.08B |
Sector | Health | Consumer Cyclical |
52-Week High | $20.38 | $106.82 |
52-Week Low | $7.60 | $78.46 |
Enterprise Value | $2.20B | $140.78B |
Volume | — | 7,493,833 |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Starbucks (SBUX) trades at $103.61, down 0.62% with a bullish technical signal despite recent price weakness. The company shows mixed fundamentals with declining net income margins (3.89% in 2025) but stable revenue growth. Recent earnings beat expectations in Q1 2026 after two consecutive misses. Analyst consensus remains positive with a $107.67 price target, though technical indicators show neutral oscillators and key resistance at $104.
SBUX faces margin pressure but benefits from strong brand loyalty and store traffic initiatives. Investment opportunity lies in international expansion and operational improvements, while risks include competitive pressures and cost inflation. The stock offers moderate upside potential with balanced analyst sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →
